PATENT CLAIM ANALYSIS

Application Number: 16027324
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "574000"]

Abstract:
Amyloid and amyloid-like proteins are found in many diseases including Alzheimer's disease, type 2 diabetes, rheumatoid arthritis, spongiform encephalopathies, and chronic renal failure. Citrate in concentrations of 0.1 mM to 10 mM can dissolve amyloid-like protein aggregates of β-2 microglobulin and amyloid β peptide (1-40)  presumably by chelating calcium. Citrate can be absorbed from the gastrointestinal tract and crosses the blood brain barrier where the concentration of citrate is two to three times the plasma concentration. Citrate administered orally or parenterally may be an effective low-risk treatment and a prevention for diseases characterized by amyloid-like deposits. Clinical trials are needed.

Claim (Index 2):
A method to prevent and treat Alzheimer's disease in a human subject comprising parenteral or oral administration of citrate to said subject.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 95.0
- Lexical Diversity: 1.3494
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12618451', '10536111', '10135592', '15026545', '11842046']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7275871190217768
- 35 USC 102 Novelty (BERT): 0.5010496940788158
- Combined Prediction Score: 0.7049333765274807
- Mean Citation Score: 161.176326
- Max Citation Score: 162.39757
- Similarity Product: 90.92884608668804

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test